Our Services
Medical Information
Helpful Resources
Published on: 3/7/2026
Empagliflozin is a well-studied medication widely recommended for type 2 diabetes, certain types of heart failure, and chronic kidney disease. It offers proven heart and kidney protection, along with modest improvements in A1C, weight, and blood pressure.
However, rare but serious risks — including euglycemic ketoacidosis, dehydration, low blood pressure, and severe genital infections — mean patients should follow medically approved safety steps: staying hydrated, monitoring blood sugar, knowing when to pause on sick days, and recognizing when urgent care is needed.
Because empagliflozin's benefits and risks vary from person to person, understanding your own symptoms is key. If you're experiencing side effects or new symptoms and aren't sure what they mean, take a free, instant, online symptom check to get personalized insights and clear guidance on your next steps.
Reviewed for medical accuracy: 07/03/2026
Not seeing your question? No worries.
Submit your own QuestionIf you've been prescribed empagliflozin and feel concerned about taking it, you're not alone. It's normal to have questions about any medication—especially one used to treat conditions like type 2 diabetes, heart failure, or chronic kidney disease.
The good news? Empagliflozin is well studied, widely used, and backed by strong clinical evidence. But like any medication, it has benefits, risks, and important safety considerations. Let's walk through what the science says and what you should do next.
Empagliflozin (brand name commonly known as Jardiance) is a prescription medication used to:
It belongs to a class of drugs called SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors).
Empagliflozin works through your kidneys. It:
This mechanism is different from insulin or many older diabetes medications.
Large clinical trials have shown that empagliflozin provides meaningful benefits beyond blood sugar control.
According to major clinical trials such as EMPA-REG OUTCOME and EMPEROR trials, empagliflozin can:
These benefits are why many medical guidelines now recommend empagliflozin early in treatment—especially for patients with heart or kidney risks.
Most people tolerate empagliflozin well. However, side effects can happen.
These occur because the medication increases glucose in urine, which can promote infections and fluid loss.
Staying hydrated and practicing good hygiene can reduce risk.
It's important not to ignore the more serious risks—but also not to panic. They are uncommon, especially when monitored appropriately.
Empagliflozin can, in rare cases, cause euglycemic diabetic ketoacidosis—a serious condition where the body produces too many ketones even if blood sugar is not extremely high.
Seek urgent medical care if you have:
This is uncommon but potentially life-threatening.
Higher urination can lead to:
This risk is higher if you:
Empagliflozin may cause a small, temporary drop in kidney function when starting the medication. In most cases, this stabilizes and provides long-term protection.
Your doctor will monitor kidney labs.
A rare but serious infection of the genital area has been reported with SGLT2 inhibitors.
It is very uncommon. Seek urgent care for:
Again, this is rare—but serious.
You should speak to a doctor immediately if you experience:
These may signal something serious or life-threatening.
If symptoms feel urgent or severe, do not wait—seek emergency care.
Many concerns about empagliflozin stem from reading long side-effect lists. It's important to understand:
Your prescribing provider considered your health profile before recommending this medication.
Empagliflozin may not be appropriate if you:
Always disclose:
If you're worried about empagliflozin, take calm, practical steps:
Ask yourself:
Understanding the reason helps reduce anxiety.
If you're taking empagliflozin:
Bring these to your doctor:
Open communication reduces uncertainty.
Many doctors recommend temporarily stopping empagliflozin during:
This helps reduce DKA risk.
Never stop long-term medication without medical advice—but ask about "sick day rules."
If you're experiencing unusual symptoms and want to better understand whether they could be related to Diabetes Mellitus, try Ubie's free AI-powered symptom checker to get personalized insights and prepare informed questions before your next doctor's appointment.
Empagliflozin is:
But it is not risk-free.
The key is informed use, monitoring, and communication with your healthcare provider.
Seek urgent care or contact a healthcare professional right away if you experience:
These may indicate life-threatening complications.
Being concerned about empagliflozin doesn't mean you should stop it. It means you care about your health.
The science shows real benefits—especially for people with type 2 diabetes, heart failure, or kidney disease. The risks are real but manageable with proper monitoring.
The best next step is simple:
Good medicine is a partnership. If you're unsure, uncomfortable, or experiencing symptoms, do not ignore them. A conversation with your healthcare provider is always the safest move.
(References)
* Butler, J., Fonarow, G. C., Zannad, F., Filippatos, G., Pitt, B., Anker, S. D., ... & American Heart Association Council on Clinical Cardiology; Council on the Kidney in Cardiovascular Disease; and Council on Hypertension. (2022). Empagliflozin in heart failure, kidney disease and diabetes: A scientific statement from the American Heart Association. *Circulation*, *146*(9), e157-e179.
* Kohli, R., Majumder, S., Tuncel, M., Sunkara, B., Nimmagadda, N., Tella, S., ... & Madan, R. (2016). Safety and tolerability of empagliflozin in patients with type 2 diabetes: a comprehensive review of clinical trials. *Current Medical Research and Opinion*, *32*(6), 1109-1117.
* Syed, Y. Y. (2015). Empagliflozin: a review of its use in the management of type 2 diabetes mellitus. *Drugs*, *75*(17), 2059-2073.
* The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin for treatment of chronic kidney disease in patients with and without diabetes. *New England Journal of Medicine*, *388*(2), 117-127.
* Zheng, X., & Kloner, R. A. (2023). A Clinical Perspective of SGLT2 Inhibitors for Renal and Cardiovascular Disease. *Clinical Cardiology*, *46*(6), 724-733.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.